Budesonide/formoterol in the treatment of asthma

References

• Partridge M, van der Molen T, Myrseth S-E, Busse W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm. Med.6(1), 13 (2006).
   PubMedGoogle Scholar
• Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur. Respir. J.19(1), 182–191 (2002).
   PubMed Web of Science ®Google Scholar
• Sovani MP, Whale CI, Oborne J et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help? Br. J. General Pract.58, 37–43 (2008).
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs64(14), 1597–1618 (2004).
   PubMed Web of Science ®Google Scholar
• Issar M, Sahasranaman S, Buchwald P, Hochhaus G. Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur. Respir. J.27(3), 511–516 (2006).
   PubMedGoogle Scholar
• Adams N, Bestall J, Jones PW. Budesonide at different doses for chronic asthma. Cochrane Database Syst. Rev.4, CD003271 (2001).
   Google Scholar
• Oborne J, Mortimer K, Hubbard RB, Tattersfield AE, Harrison TW. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am. J. Respir. Crit. Care Med.180(7), 598–602 (2009).
   PubMed Web of Science ®Google Scholar
• Juniper E, Kline P, Vanzieleghem M et al. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur. Respir. J.3(10), 1122–1127 (1990).
   PubMed Web of Science ®Google Scholar
• Kips JC, O’Connor BJ, Inman MD et al. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am. J. Respir. Crit. Care Med.161(3), 996–1001 (2000).
   PubMed Web of Science ®Google Scholar
• Sears MR, Lotvall J. Past, present and future – β2-adrenoceptor agonists in asthma management. Respir. Med.99(2), 152–170 (2005).
   PubMed Web of Science ®Google Scholar
• Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lotvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm. Pharmacol. Ther.14(1), 29–34 (2001).
   PubMed Web of Science ®Google Scholar
• Lotvall J, Ankerst J. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients. Respir. Med.102(3), 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Totterman K, Huhti L, Sutinen E et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur. Respir. J.12(3), 573–579 (1998).
   PubMed Web of Science ®Google Scholar
• Cheung D, van Klink HC, Aalbers R. Improved lung function and symptom control with formoterol on demand in asthma. Eur. Respir. J.27(3), 504–510 (2006).
   PubMed Web of Science ®Google Scholar
• Lindmark B. Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma. Ther. Adv. Respir. Dis.2(5), 279–299 (2008).
   PubMedGoogle Scholar
• Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med.160(1), 244–249 (1999).
   PubMed Web of Science ®Google Scholar
• Maneechotesuwan K, Essilfie-Quaye S, Meah S et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest128(4), 1936–1942 (2005).
   PubMed Web of Science ®Google Scholar
• Usmani OS, Ito K, Maneechotesuwan K et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am. J. Respir. Crit. Care Med.172(6), 704–712 (2005).
   PubMed Web of Science ®Google Scholar
• Eklund A, Tronde A, Johannes-Hellberg I, Gillen M, Borgstrom L. Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults. Biopharm. Drug Dispos.29(7), 382–395 (2008).
   PubMedGoogle Scholar
• Harrison TW, Tattersfield AE. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax58(3), 258–260 (2003).
   PubMedGoogle Scholar
• McGavin JK, Goa KL, Jarvis B. Inhaled budesonide/formoterol combination. Drugs61(1), 71–78; discussion 79–80 (2001).
   PubMed Web of Science ®Google Scholar
• Tronde A, Gillen M, Borgstrom L, Lotvall J, Ankerst J. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD. J. Clin. Pharmacol.48(11), 1300–1308 (2008).
   PubMedGoogle Scholar
• Ni Chroinin M, Greenstone IR, Danish A et al. Long-acting β2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst. Rev.4, CD005535 (2005).
   Google Scholar
• Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of inhaled long-acting β2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst. Rev.4, CD005307 (2009).
   Google Scholar
• Noonan M, Rosenwasser LJ, Martin P, O’Brien CD, O’Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs66(17), 2235–2254 (2006).
   PubMed Web of Science ®Google Scholar
• Corren J, Korenblat PE, Miller CJ, O’Brien CD, Mezzanotte WS. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin. Ther.29(5), 823–843 (2007).
   PubMed Web of Science ®Google Scholar
• Zetterstrom O, Buhl R, Mellem H et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur. Respir. J.18(2), 262–268 (2001).
   PubMed Web of Science ®Google Scholar
• Buhl R, Creemers JP, Vondra V et al. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir. Med.97(4), 323–330 (2003).
   PubMed Web of Science ®Google Scholar
• Kuna P, Creemers JP, Vondra V et al. Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma. Respir. Med.100(12), 2151–2159 (2006).
   PubMedGoogle Scholar
• Lalloo UG, Malolepszy J, Kozma D et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest123(5), 1480–1487 (2003).
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Bisgaard H, Godard PP et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am. J. Respir. Crit. Care Med.171(2), 129–136 (2005).
   PubMed Web of Science ®Google Scholar
• Fitzgerald JM, Sears MR, Boulet LP et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can. Respir. J.10(8), 427–434 (2003).
   PubMedGoogle Scholar
• Canonica GW, Castellani P, Cazzola M et al. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulm. Pharmacol. Ther.17(4), 239–247 (2004).
   PubMed Web of Science ®Google Scholar
• Ind PW, Haughney J, Price D, Rosen JP, Kennelly J. Adjustable and fixed dosing with budesonide/ formoterol via a single inhaler in asthma patients: the ASSURE study. Respir. Med.98(5), 464–475 (2004).
   PubMed Web of Science ®Google Scholar
• Aalbers R, Backer V, Kava TT et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr. Med. Res. Opin.20(2), 225–240 (2004).
   PubMed Web of Science ®Google Scholar
• Fitzgerald JM, Boulet LP, Follows RM. The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin. Ther.27(4), 393–406 (2005).
   PubMed Web of Science ®Google Scholar
• Scicchitano R, Aalbers R, Ukena D et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr. Med. Res. Opin.20(9), 1403–1418 (2004).
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, D’Urzo A, Pauwels R et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur. Respir. J.26(5), 819–828 (2005).
   PubMed Web of Science ®Google Scholar
• Rabe KF, Pizzichini E, Stallberg B et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest129(2), 246–256 (2006).
   PubMed Web of Science ®Google Scholar
• Lundborg M, Wille S, Bjermer L et al. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost–effectiveness study. Curr. Med. Res. Opin.22(5), 809–821 (2006).
   PubMed Web of Science ®Google Scholar
• Rabe KF, Atienza T, Magyar P et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet368(9537), 744–753 (2006).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Boulet LP, Peters MJ et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir. Med.101(12), 2437–2446 (2007).
   PubMed Web of Science ®Google Scholar
• Kuna P, Peters MJ, Manjra AI et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int. J. Clin. Pract.61(5), 725–736 (2007).
   PubMed Web of Science ®Google Scholar
• Demoly P, Louis R, Soes-Petersen U et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respir. Med.103(11), 1623–1632 (2009).
   PubMed Web of Science ®Google Scholar
• Pavord ID, Jeffery PK, Qiu Y et al. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. J. Allergy Clin. Immunol.123(5), 1083–1089 (2009).
   PubMed Web of Science ®Google Scholar
• Edwards SJ, Maltzahn Rv, Naya IP, Harrison T. Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials. Int. J. Clin. Pract.64(5), 619–627 (2010).
   PubMed Web of Science ®Google Scholar
• Boonsawat W, Charoenratanakul S, Pothirat C et al. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir. Med.97(9), 1067–1074 (2003).
   PubMed Web of Science ®Google Scholar
• Balanag VM, Yunus F, Yang PC, Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm. Pharmacol. Ther.19(2), 139–147 (2006).
   PubMed Web of Science ®Google Scholar
• Bateman ED, Fairall L, Lombardi DM, English R. Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respir. Res.7, 13 (2006).
   PubMed Web of Science ®Google Scholar
• Mortimer KJ, Harrison TW, Tang Y et al. Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. Br. J. Clin. Pharmacol.62(4), 412–419 (2006).
   PubMed Web of Science ®Google Scholar
• Donnelly R, Williams KM, Baker AB et al. Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose-response study. Am. J. Respir. Crit. Care Med.156(6), 1746–1751 (1997).
   PubMed Web of Science ®Google Scholar
• Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K. Safety of inhaled corticosteroids. Proc. Am. Thorac.Soc.1(3), 171–175 (2004).
   PubMedGoogle Scholar
• Sovani MP, Whale CI, Tattersfield AE. A benefit–risk assessment of inhaled long-acting β2-agonists in the management of obstructive pulmonary disease. Drug Saf.27(10), 689–715 (2004).
   PubMed Web of Science ®Google Scholar
• Mortimer KJ, Tattersfield AE. Benefit versus risk for oral, inhaled, and nasal glucocorticosteroids. Immunol. Allergy Clin. North Am.25(3), 523–539 (2005).
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial. Chest129(1), 15–26 (2006).
   PubMed Web of Science ®Google Scholar
• Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst. Rev.4, CD006923 (2008).
   Google Scholar
• Bateman E, Nelson H, Bousquet J et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann. Intern. Med.149(1), 33–42 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson H, Bonuccelli C, Radner F et al. Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials. J. Allergy Clin. Immunol.125(2), 390–396.e8 (2010).
   PubMed Web of Science ®Google Scholar